The structural component of Gram- bacteria, endotoxin (ET), induces the release of endogenous mediators of sepsis. Attempts to remove these downstream molecules in vivo, have not improved survival. However, extracorporeal strategies such as continuous renal replacement therapy or therapeutic plasmapheresis have shown benefit. We are presenting an affinity-based extracorporeal technology for the removal of ET from whole blood. The small-scale device contains an adsorbent that removed 75% of ET present in whole blood. This affinity resin displayed good hemocompatibility regarding the coagulation pathway. Minimal platelet, neutrophil and complement activation were observed. There was also no evidence of consumption of coagulation factors or cell loss. In as much as ET participates in both the inflammatory and coagulation abnormalities in sepsis, this method represents an efficient and hemocompatible way to remove ET from whole blood, which, in an extracorporeal setting, may improve the outcome of sepsis.
AngusD.C., Linde-ZwirbleW.T., LidickerJ., ClermontG., CarcilloJ., PinskyM.R.. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care.Crit Care Med2001; 29: 1303–10.
2.
VincentJ.L., SunQ., DuboisM.J.. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.Clin Infect Dis2002; 34: 1084–93.
3.
StegmayrB.G.. Is there a future for adsorption techniques in sepsis?Blood Purif2000; 18: 149–55.
4.
BerlotG., LucangeloU., GalimbertiG., SgangaG.. Plasma-pheresis in sepsis.Contrib Nephrol2001; 132: 391–9.
5.
StegmayrB.G.. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome.Ther Apher2001; 5: 123–7.
6.
TettaC., GianottiL., CavaillonJ.M.. Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock.Crit Care Med2000; 28: 1526–33.
7.
TettaC., BellomoR., BrendolanA.. Use of adsorptive mechanisms in continuous renal replacement therapies in the critically ill.Kidney Int1999; 72(Suppl): S15–9.
8.
BellomoR., RoncoC.. Continuous renal replacement therapy in the intensive care unit.Intensive Care Med1999; 25: 781–9.
9.
ZimmermannM., BuschK., KuhnS., ZeppezauerM.. Endotoxin adsorbent based on immobilized human serum albumin.Clin Chem Lab Med1999; 37: 373–9.
10.
ShojiH.. Extracorporeal endotoxin removal for the treatment of sepsis: Endotoxin adsorption cartridge (Toraymyxin).Therap Apher Dial2003; 7: 108–14.
11.
StaubachK.H., BoehmeM., ZimmermannM., OttoV.. A new endotoxin adsorption device in Gram-negative sepsis: Use of immobilized albumin with the MATISSE adsorber.Transfus Apheresis Sci2003; 29: 93–8.
12.
AmoureuxM.C., HegyiE., LeD.. A new method for removing endotoxin from plasma using a hemocompatible affinity chromatography technology, applicable for extracorporeal treatment of septic patients.J Endotoxin Res2004; 10: 85–95.
13.
SiamiG.A., SiamiF.S.. Membrane plasmapheresis in the United States: A review over the last 20 years.Ther Apher2001; 5: 315–20.
14.
StrandS.E., SjogrenH.O., ChenJ.. In: AbramsP.G., FritzbergA.R., eds. Extracorporeal techniques in radio-immunotherapy.NY: Marcel & Dekker, 2000: pp. 223–43.
15.
RinderC.S., GaalD., StudentL.A., SmithB.R.. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass.J Thorac Cardiovasc Surg1994; 107: 280–8.
16.
MezzanoD., HabashJ., ArandaE.. Platelet consumption and platelet dysfunction during and after surgery with extracorporeal circulation.Sangre1986, 31: 425–34.
17.
RinderC.S., BohnertJ., RinderH.M., MitchellJ., AultK., HillmanR.. Platelet activation and aggregation during cardiopulmonary bypass.Anesthesiology1991; 75: 388–93.
18.
HarkerL.A., MalpassT.W., BransonH.E., HesselE.A., SlichterS.J.. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release.Blood1980; 56: 824–34.
19.
BoschT., SchmidtB., SpencerP.C.. Ex vivo biocompatibility evaluation of a new modified cellulose membrane.Artif Organs1987; 11: 144–8.
20.
BoschT., SchmidtB., KleophasW., OttoV., SamtlebenW.. LDL hemoperfusion, a new procedure for LDL apheresis: Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients.Artif Organs1997; 21: 1060–5.
21.
BoschT., LennertzA., DuhrC., FinkE., SamtlebenW.. Ex vivo biocompatibility of avidin-agarose: A new device for direct adsorption of biotinylated antibodies from human whole blood.Artif Organs2000; 24: 696–704.
22.
ParkK.D., SuzukiK., LeeW.K.. Platelet adhesion and activation on polyethylene glycol modified polyurethane surfaces. Measurement of cytoplasmic calcium.ASAIO J1996; 42: M876–81.
23.
ZhangM., DesaiT., FerrariM.. Proteins and cells on PEG immobilized silicon surfaces.Biomaterials1998; 19: 953–60.
24.
VladkovaT., KrastevaN., KostadinovaA., AltankovG.. Preparation of PEG-coated surfaces and a study for their interaction with living cells.J Biomater Sci Polym Ed1999; 10: 609–20.
25.
DeibleC.R., PetroskoP., JohnsonP.C., BeckmanE.J., RussellA.J., WagnerW.R.. Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol.Biomaterials1999, 20: 101–9.
SirolliV., Di StanteS., StuardS.. Biocompatiblity and functional performance of a polyethylene glycol acid-grafted cellulosic membrane for hemodialysis.Int J Artif Organs2000; 23: 356–64.
28.
Uchida, YamatoM., ItoE.. Two different types of nonthrombogenic surfaces: PEG suppresses platelet adhesion ATP-independently but HEMA-St block copolymer requires ATP consumption of platelets to prevent adhesion.J Biomed Mater Res2000; 50: 585–90.
29.
MichelsonA.D., BarnardM.R., HechtmanH.B.. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.Proc Natl Acad Sci USA1996; 93: 11877–82.
30.
OpalS.M., ScannonP.J., VincentJ.L.. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.J Infect Dis1999; 180: 1584–9.
31.
KodamaM.. Hemoperfusion using a polymyxin B immobilized fiber column for the removal of endotoxin. In: LevinJ., AlvingC.R., MunfordR.S., StutzP.L., eds. Bacterial endotoxin: Recognition and effector mechanisms1993; pp. 389–98.
32.
ShalabyM.R., WaageA., AardenL., EspevikT.. An overview of the history and biologic properties of tumor necrosis factors.Spring Semin Immunopathol1986; 9: 33–7.
